05:25 PM EST, 12/11/2024 (MT Newswires) -- Corcept Therapeutics ( CORT ) said late Wednesday a phase 2 trial assessing two doses -- 150 milligrams and 300 milligrams -- of dazucorilant in people with amyotrophic lateral sclerosis didn't meet its primary endpoint.

The primary endpoint was the change from baseline in the amyotrophic lateral sclerosis functional rating scale-revised in people who were given dazucorilant compared with those who received placebo, the company said.

The company also said people who were administered dazucorilant "experienced substantially more gastrointestinal upset at the onset of treatment than those who received placebo."

Upon completion of the 24-week study, patients were eligible to enter a long-term extension study in which they were given 300 milligrams of dazucorilant, the company said.

Corcept said the long-term extension study will proceed and overall survival will be evaluated in March 2025.

The shares of Corcept Therapeutics ( CORT ) were falling 2% in after-hours trading.